<?xml version="1.0"?>
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20190208//EN"
       "JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.4" xml:lang="en">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">Acta biomedica scientifica</journal-id>
   <journal-title-group>
    <journal-title xml:lang="en">Acta biomedica scientifica</journal-title>
    <trans-title-group xml:lang="ru">
     <trans-title>Acta biomedica scientifica</trans-title>
    </trans-title-group>
   </journal-title-group>
   <issn publication-format="print">2541-9420</issn>
   <issn publication-format="online">2587-9596</issn>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">14823</article-id>
   <article-id pub-id-type="doi">10.12737/23790</article-id>
   <article-categories>
    <subj-group subj-group-type="toc-heading" xml:lang="ru">
     <subject>Клиническая медицина</subject>
    </subj-group>
    <subj-group subj-group-type="toc-heading" xml:lang="en">
     <subject>Clinical Medicine</subject>
    </subj-group>
    <subj-group>
     <subject>Клиническая медицина</subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">ABNORMALITY OF LIPID METABOLISM IN PATIENTS WITH DIABETES MELLITUS TYPE 1 AND POOR GLYCEMIC CONTROL WITH AND WITHOUT DIABETIC MICROANGIOPATHIES</article-title>
    <trans-title-group xml:lang="ru">
     <trans-title>ОСОБЕННОСТИ ЛИПИДНОГО ОБМЕНА У ПАЦИЕНТОВ С САХАРНЫМ ДИАБЕТОМ 1-ГО ТИПА С НЕУДОВЛЕТВОРИТЕЛЬНЫМ ГЛИКЕМИЧЕСКИМ КОНТРОЛЕМ  С ДИАБЕТИЧЕСКИМИ МИКРОАНГИОПАТИЯМИ И БЕЗ НИХ</trans-title>
    </trans-title-group>
   </title-group>
   <contrib-group content-type="authors">
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Хамнуева</surname>
       <given-names>Лариса Юрьевна</given-names>
      </name>
      <name xml:lang="en">
       <surname>Khamnueva</surname>
       <given-names>Larisa Юрьевна</given-names>
      </name>
     </name-alternatives>
     <email>hamnueval@mail.ru</email>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Съемщиков</surname>
       <given-names>Владимир Сергеевич</given-names>
      </name>
      <name xml:lang="en">
       <surname>Syomshchikov</surname>
       <given-names>Vladimir Сергеевич</given-names>
      </name>
     </name-alternatives>
     <email>svs2491@mail.ru</email>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Чугунова</surname>
       <given-names>Елена Владимировна</given-names>
      </name>
      <name xml:lang="en">
       <surname>Chugunova</surname>
       <given-names>Elena Владимировна</given-names>
      </name>
     </name-alternatives>
     <email>E.V_Chugunova@mail.ru</email>
    </contrib>
   </contrib-group>
   <pub-date publication-format="print" date-type="pub" iso-8601-date="2016-12-26T00:00:00+03:00">
    <day>26</day>
    <month>12</month>
    <year>2016</year>
   </pub-date>
   <pub-date publication-format="electronic" date-type="pub" iso-8601-date="2016-12-26T00:00:00+03:00">
    <day>26</day>
    <month>12</month>
    <year>2016</year>
   </pub-date>
   <volume>1</volume>
   <issue>6</issue>
   <fpage>113</fpage>
   <lpage>117</lpage>
   <self-uri xlink:href="https://zh-szf.ru/en/nauka/article/14823/view">https://zh-szf.ru/en/nauka/article/14823/view</self-uri>
   <abstract xml:lang="ru">
    <p>С целью изучения особенностей липидного обмена у пациентов с сахарным диабетом (СД) 1-готипапроведён ретроспективный анализ данных историй болезни 106пациентов, находившихся на лечении в эндокринологическом отделении ГБУЗ «Иркутская ордена «Знак Почёта» областная клиническая больница». Исследованы уровни липидов, гликированного гемоглобина (HbA1c). Дислипидемия наблюдалось у 81пациентa при неудовлетворительном контроле СД 1типа. У больных СД 1типа с микрососудистыми осложнениями, с артериальной гипертензией и уровнем HbA1c&amp;#62;8% уровни атерогенных липидов значимо выше. </p>
   </abstract>
   <trans-abstract xml:lang="en">
    <p>Hyperglycemia and dyslipidemia are common metabolic abnormalities in adults with type 1 diabetes mellitus (T1DM) and both increase cardiovascular disease risk. Normalization of lipid metabolism is a mandatory element in preven-tion of diabetic micro- and macroangiopathies in patients with T1DM and it is directly related to improvement of health outcome. We aimed to investigate serum lipid profiles in patients with T1DM and poor glycemic control. Among observed patients with T1DM, 76% were classified as having dyslipidemia, dyslipidemia rate was higher in patients with diabetic microangiopathies. Patients with T1DM and microvascular complications, arterial hypertension (AH) and the level of glycated hemoglobin (HbA1c) &amp;#62;8% had significantly higher levels of total cholesterol (TC), very low density lipoproteins (VLDL), triglycerides (TG) and non-high density lipoproteins (non-HDL). Therefore, management of patients with T1DM at the outpatient stage requires a strict control of lipid metabolism.</p>
   </trans-abstract>
   <kwd-group xml:lang="ru">
    <kwd>сахарный диабет</kwd>
    <kwd>дислипидемия</kwd>
    <kwd>холестерин</kwd>
    <kwd>ЛПВП</kwd>
    <kwd>ЛПНП</kwd>
    <kwd>ЛПОНП</kwd>
    <kwd>триглицериды</kwd>
    <kwd>хо-лестерин не-ЛПВП</kwd>
   </kwd-group>
   <kwd-group xml:lang="en">
    <kwd>diabetes mellitus</kwd>
    <kwd>dyslipidemia</kwd>
    <kwd>cholesterol</kwd>
    <kwd>HDL</kwd>
    <kwd>LDL</kwd>
    <kwd>VLDL</kwd>
    <kwd>triglycerides</kwd>
    <kwd>non-HDL</kwd>
   </kwd-group>
  </article-meta>
 </front>
 <body>
  <p></p>
 </body>
 <back>
  <ref-list>
   <ref id="B1">
    <label>1.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Алгоритмы специализированной медицинской помощи больным сахарным диабетом (7-й выпуск) / Под ред. И.И.Дедова, М.В.Шестаковой //Сахарный диабет. - 2015. - Т.18. - No1S. - 112с.</mixed-citation>
     <mixed-citation xml:lang="en">DedovII, ShestakovaMV (eds.) (2015). Standards of specialized diabetes care [Algoritmy spetsializirovannoy meditsinskoy pomoshchi bol’nym sakharnym diabetom (7-y vypusk)]. Sakharnyy diabet, 18(1S), 112.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B2">
    <label>2.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Сахарный диабет: острые и хронические осложнения /Под ред. И.И.Дедова, М.В.Шестако-вой.- М.: Медицинское информационное агентство, 2012. - 480с.</mixed-citation>
     <mixed-citation xml:lang="en">DedovII, ShestakovaMV (eds.) (2012). Diabetes mellitus: acute and chronic complications [Sakharnyy diabet: ostrye i khronicheskie oslozhneniya],480.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B3">
    <label>3.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">СамойловаЮ.Г., ЮрченкоЕ.В. Особенности липидного обмена у пациентов с сахарным диабетом 1-го типа в зависимости от наличия диабетических микроангиопатий и характера питания //Бюллетеньсибирской медицины. - 2014. - No5. - С.87-92.</mixed-citation>
     <mixed-citation xml:lang="en">SamoylovaYG, YurchenkoEV (2014). Features of lipid metabolism in patients with type 1 diabetes, depending on diabetic microvascular complications and diet [Osobennosti lipidnogo obmena u patsientov s sakharnym diabetom 1-go tipa v zavisimosti ot nalichiya diabeticheskikh mikroangiopatiy i kharaktera pitaniya]. Byulleten’ sibirskoy meditsiny, (5) 87-92</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B4">
    <label>4.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru"></mixed-citation>
     <mixed-citation xml:lang="en">ACCORD Study Group and ACCORD Eye Study Group. (2012). Effects of medical therapies on retinopathy progression in type 2 diabetes. N.Engl. J.Med., 367(25), 2458.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B5">
    <label>5.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru"></mixed-citation>
     <mixed-citation xml:lang="en">American Diabetes Association (2014). Executive summary: Standards of medical care indiabetes - 2014. Diabetes Care, 37(1), 5-13.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B6">
    <label>6.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru"></mixed-citation>
     <mixed-citation xml:lang="en">ChowdhuryTA, HopkinsD, DodsonPM, VafidisGC (2002). The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy? Eye (Lond.), 16(6), 689-693.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B7">
    <label>7.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru"></mixed-citation>
     <mixed-citation xml:lang="en">DaaeLN, VierultP, LandaasS, UrdalP (1993). Cardiovascular risk factors: interactive effect of lipids, coagulation and fibrinolysis. Scand.J.Clin.Lab.Invest.,(215), 19-27.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B8">
    <label>8.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru"></mixed-citation>
     <mixed-citation xml:lang="en">Expert Dyslipidemia Panel, GrundySM (2013). An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia. J. Clin. Lipidol., 7(6), 561-565</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B9">
    <label>9.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru"></mixed-citation>
     <mixed-citation xml:lang="en">HoffinerSM (1993). Lipoprotein (a) and diabetes. An update. Diabetes Care, (16), 835-843.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B10">
    <label>10.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru"></mixed-citation>
     <mixed-citation xml:lang="en">KeechAC, MitchellP, SummanenPA, O’DayJ,DavisTM, MoffittMS, TaskinenMR, SimesRJ, TseD,WilliamsonE, MerrifieldA, LaatikainenLT, d’EmdenMC,CrimetDC, O’ConnellRL, ColmanPG, FIELD study investigators. (2007). Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet, 370(9600), 1687-1697.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B11">
    <label>11.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru"></mixed-citation>
     <mixed-citation xml:lang="en">KhawKT, WarehamN, BinghamS, LubenR, WelchA, DayN (2004). Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk. Ann. Intern. Med., (141), 413-420.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B12">
    <label>12.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru"></mixed-citation>
     <mixed-citation xml:lang="en">KimSH, JungIA, JeonYJ, ChoWK, ChoKS, ParkSH,JungMH, SuhBK (2014). Serum lipid profiles and glycemic control in adolescents and young adults with type 1 diabetes mellitus. Ann. Pediatr. Endocrinol. Metab., (19), 191-196</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B13">
    <label>13.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru"></mixed-citation>
     <mixed-citation xml:lang="en">MaahsDM, OgdenLG, DabeleaD (2010).Association of glycaemia with lipids in adults with type 1 diabetes: modification by dyslipidaemia medication. Diabetologia, 53(12), 2518-2525.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B14">
    <label>14.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru"></mixed-citation>
     <mixed-citation xml:lang="en">MuntnerP, CoreshJ, SmithJC, EckfeldtJ, KlagMJ (2000). Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int., 58(1), 293-301.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B15">
    <label>15.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru"></mixed-citation>
     <mixed-citation xml:lang="en">ThomasMC, Rosengard-BarlundM, MillsV,RönnbackM, ThomasS, ForsblomC, CooperME,TaskinenMR, VibertiG, GroopPH (2006). Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care, 29(2), 317-322</mixed-citation>
    </citation-alternatives>
   </ref>
  </ref-list>
 </back>
</article>
